Nemluvio Shows Durable Three-Year Responses in Atopic Dermatitis
At Fall Clinical 2026, Galderma presented three-year Nemluvio data showing deep, lasting skin lesion and itch responses in atopic dermatitis patients aged 12 and older.
Topic
Galderma
Topic
Galderma
Galderma Presents New Nemluvio Data in Atopic Dermatitis Aged 12+
Galderma has presented new Nemluvio (nemolizumab) data showing responses in patients with atopic dermatitis aged 12 and older, ad…
Nemluvio Delivers Sustained Improvement in Moderate-to-Severe Atopic Dermatitis
Galderma reports Nemluvio (nemolizumab) delivered sustained improvements in moderate-to-severe atopic dermatitis, reinforcing the…
Nemolizumab Shows Sustained Atopic Dermatitis Gains at 152 Weeks in ARCADIA
Galderma reports 152-week ARCADIA data showing nemolizumab maintained improvements in lesions, itch, sleep and quality of life in…
Nemolizumab Shows Sustained Atopic Dermatitis Benefit to Three Years
Galderma reports at EADV 2026 that nemolizumab (Nemluvio) delivered sustained improvements in moderate-to-severe atopic dermatiti…
Nemolizumab Sustains Atopic Dermatitis Improvements Through Three Years
Galderma's EADV 2026 data show Nemluvio (nemolizumab) sustained improvements in moderate-to-severe atopic dermatitis for up to th…